These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34751140)

  • 21. Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.
    Jackson RJ; Rudinskiy N; Herrmann AG; Croft S; Kim JM; Petrova V; Ramos-Rodriguez JJ; Pitstick R; Wegmann S; Garcia-Alloza M; Carlson GA; Hyman BT; Spires-Jones TL
    Eur J Neurosci; 2016 Dec; 44(12):3056-3066. PubMed ID: 27748574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
    Silvestro S; Valeri A; Mazzon E
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent update on the heterogeneity of the Alzheimer's disease spectrum.
    Jellinger KA
    J Neural Transm (Vienna); 2022 Jan; 129(1):1-24. PubMed ID: 34919190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An automated method measures variability in P-glycoprotein and ABCG2 densities across brain regions and brain matter.
    Kannan P; Schain M; Kretzschmar WW; Weidner L; Mitsios N; Gulyás B; Blom H; Gottesman MM; Innis RB; Hall MD; Mulder J
    J Cereb Blood Flow Metab; 2017 Jun; 37(6):2062-2075. PubMed ID: 27488911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biological Signatures of Alzheimer's Disease.
    Sharma P; Sharma A; Fayaz F; Wakode S; Pottoo FH
    Curr Top Med Chem; 2020; 20(9):770-781. PubMed ID: 32108008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From Small Peptides to Large Proteins against Alzheimer'sDisease.
    Picone P; Sanfilippo T; Vasto S; Baldassano S; Guggino R; Nuzzo D; Bulone D; San Biagio PL; Muscolino E; Monastero R; Dispenza C; Giacomazza D
    Biomolecules; 2022 Sep; 12(10):. PubMed ID: 36291553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease.
    Nicoll JAR; Buckland GR; Harrison CH; Page A; Harris S; Love S; Neal JW; Holmes C; Boche D
    Brain; 2019 Jul; 142(7):2113-2126. PubMed ID: 31157360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular imaging of beta-amyloid plaques in the brain].
    Ono M
    Brain Nerve; 2007 Mar; 59(3):233-40. PubMed ID: 17370649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Unifying Hypothesis for Alzheimer's Disease: From Plaques to Neurodegeneration.
    Edwards FA
    Trends Neurosci; 2019 May; 42(5):310-322. PubMed ID: 31006494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Senile dementia associated with amyloid beta protein angiopathy and tau perivascular pathology but not neuritic plaques in patients homozygous for the APOE-epsilon4 allele.
    Vidal R; Calero M; Piccardo P; Farlow MR; Unverzagt FW; Méndez E; Jiménez-Huete A; Beavis R; Gallo G; Gomez-Tortosa E; Ghiso J; Hyman BT; Frangione B; Ghetti B
    Acta Neuropathol; 2000 Jul; 100(1):1-12. PubMed ID: 10912914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gray to white matter signal ratio as a novel biomarker of neurodegeneration in Alzheimer's disease.
    Putcha D; Katsumi Y; Brickhouse M; Flaherty R; Salat DH; Touroutoglou A; Dickerson BC
    Neuroimage Clin; 2023; 37():103303. PubMed ID: 36586361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloid dye pairs as spectral sensors for enhanced detection and differentiation of misfolded proteins.
    Stepanchuk AA; Stys PK
    J Photochem Photobiol B; 2023 Nov; 248():112786. PubMed ID: 37742497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular interaction between type 2 diabetes and Alzheimer's disease through cross-seeding of protein misfolding.
    Moreno-Gonzalez I; Edwards Iii G; Salvadores N; Shahnawaz M; Diaz-Espinoza R; Soto C
    Mol Psychiatry; 2017 Sep; 22(9):1327-1334. PubMed ID: 28044060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry.
    Kaya I; Zetterberg H; Blennow K; Hanrieder J
    ACS Chem Neurosci; 2018 Jul; 9(7):1802-1817. PubMed ID: 29648443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Label-free vibrational imaging of different Aβ plaque types in Alzheimer's disease reveals sequential events in plaque development.
    Röhr D; Boon BDC; Schuler M; Kremer K; Hoozemans JJM; Bouwman FH; El-Mashtoly SF; Nabers A; Großerueschkamp F; Rozemuller AJM; Gerwert K
    Acta Neuropathol Commun; 2020 Dec; 8(1):222. PubMed ID: 33308303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of deposition of tau and amyloid-β proteins with structural connectivity changes in cognitively normal older adults and Alzheimer's disease spectrum patients.
    Shigemoto Y; Sone D; Maikusa N; Okamura N; Furumoto S; Kudo Y; Ogawa M; Takano H; Yokoi Y; Sakata M; Tsukamoto T; Kato K; Sato N; Matsuda H
    Brain Behav; 2018 Dec; 8(12):e01145. PubMed ID: 30358161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tau-related grey matter network breakdown across the Alzheimer's disease continuum.
    Pelkmans W; Ossenkoppele R; Dicks E; Strandberg O; Barkhof F; Tijms BM; Pereira JB; Hansson O
    Alzheimers Res Ther; 2021 Aug; 13(1):138. PubMed ID: 34389066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients.
    Kung MP; Skovronsky DM; Hou C; Zhuang ZP; Gur TL; Zhang B; Trojanowski JQ; Lee VM; Kung HF
    J Mol Neurosci; 2003 Feb; 20(1):15-24. PubMed ID: 12663930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.